drug · antibody drug conjugate
tisotumab vedotin
Marketedupdated 3mo agoby Genmab AS🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
indications
investigational
NSCLC
targets
Tissue factorTubulin
all catalysts(4)
approval · 4
Sep 20, 2021
approval
TIVDAK (TISOTUMAB VEDOTIN-TFTV) — FDA approval
tisotumab vedotin
→
Jul 26, 2023
approval
TIVDAK (TISOTUMAB VEDOTIN-TFTV) — FDA approval
tisotumab vedotin
→
Apr 29, 2024
approval
TIVDAK (TISOTUMAB VEDOTIN-TFTV) — FDA approval
tisotumab vedotin
→
Nov 12, 2025
approval
TIVDAK (TISOTUMAB VEDOTIN-TFTV) — FDA approval
tisotumab vedotin
→
Trials studying tisotumab vedotin
- phase3A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- phase2Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
- phase4Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
- phase2Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
- phase3Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
- phase1To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
- phase2A Trial of Tisotumab Vedotin in Cervical Cancer
News(1)
- Pfizer expands multibillion-dollar cost-cutting planHatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.biopharma_dive · 10d ago
Data sources
last refreshed 48m ago
Found something off?
comments(0)
5-min edit window · permanent after that